The researchers involved in this axis develop and use new imaging approaches based on technologies such as positron emission tomography (PET), tomodensitomety (TDM), magnetic resonance imaging (MRI), optical imaging, and electroencephalography (EEG).
These imaging methods represent powerful screening tools for early diagnosis, therapeutic management, and personalized medicine.
Preclinical imaging with animal models and clinical imaging with humans are used to study cancer and metabolic, cardiovascular, and neurological disorders.
A major portion of the research effort deployed in this axis focuses on developing new devices and on the reconstruction, analysis, modeling, and processing of images generated by various imaging means.
Its researchers are also working on synthesizing new radiotracers, contrast agents, and radiosensitivity agents, as well as developing preclinical and clinical trials to validate these substances resulting from research prior to their marketing.
Axis Director | Roger Lecomte, PhD
Axis Coordinator | Catherine M. Pépin
- Development of specific instrumentation and methodology for µTEP, µTDM, and optical technologies
- Development of methods for the reconstruction, analysis, modeling, and processing of information to reconstitute medical images
- Cyclotron production of radioisotopes (e.g., 99mTc) and development of radiotracers for diagnosis and therapeutic management
- Development of biomarkers and molecular probes to screen for cancer and metabolic, cardiovascular, and cerebral disorders
- Development of preclinical models to study cancer and metabolic, cardiovascular, and cerebral disorders
- Clinical use of PET, TDM, MRI, EEG, and optical imaging
Cyclotron Production of Technetium
The May 2009 closure of the Chalk River nuclear reactor in Ontario caused a technetium-99m shortage that alarmed a large number of nuclear-medicine specialists, primarily in North America, because the situation delayed many medical diagnoses that were deemed urgent.
During this crisis, CRCELB researchers—including Brigitte Guérin, Johan van Lier, Roger Lecomte, and Éric E. Turcotte—demonstrated that the 99mTc produced with their low-energy cyclotron (TR19) yielded results completely equivalent to those achieved with technetium from a nuclear reactor.